Payment overview · 2025
General Payments
$365.34
17 reported records · 9 companies
Healthcare provider profile · identity verified
Lee R Pennington, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BETHESDA, MD · NPI 1548259997
Verified facts
What the public records show
CMS Open Payments records show Lee R Pennington, MD received $365.34 in general payments during 2025 across 17 reported records.
Sumitomo Pharma America, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nexletol.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $93.90 | 25.7% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.32 | 18.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.08 | 13.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.24 | 11.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.44 | 8.9% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $21.71 | 5.9% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $20.95 | 5.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.72 | 5.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.98 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.34 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $93.90 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.32 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.24 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $20.98 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
90 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 36 |
| Ezetimibe | Ezetimibe | 111 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 93 | 30 |
| Eliquis | Apixaban | 90 | 21 |
| Telmisartan | Telmisartan | 82 | 23 |
| Losartan Potassium | Losartan Potassium | 70 | 24 |
| Metformin Hcl Er | Metformin Hcl | 58 | 19 |
| Ozempic | Semaglutide | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 17 |
| Gabapentin | Gabapentin | 47 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 14 |
| Allopurinol | Allopurinol | 45 | 14 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 12 |
| Carvedilol | Carvedilol | 41 | 12 |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Furosemide | Furosemide | 40 | 11 |
| Trazodone Hcl | Trazodone Hcl | 40 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | 15 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Simvastatin | Simvastatin | 32 | 11 |
| Cefuroxime | Cefuroxime Axetil | 31 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 22 |
| Repaglinide | Repaglinide | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | 11 |
| Prednisone | Prednisone | 25 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Zaleplon | Zaleplon | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Omeprazole | Omeprazole | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.34 · 17 records | Sumitomo Pharma America, Inc. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, Fluad, Flucelvax, GEMTESA, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, Tymlos, UBRELVY | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error